maravai lifesciences holdings glp-1 receptor agonist medications Agonists: The New Wave in Diabetes Management Mapping the effectiveness and risks
Description
Scheen has received lecturer/scientific advisor/clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and NovoNordisk, and has worked as a clinical investigator in the EMPA-REG OUTCOME, CANVAS-R, DECLARE-TIMI 58, LEADER and HARMONY Outcomes cardiovascular outcome trials
GLP-1 receptor agonists have also been shown to cause weight loss in some individuals
[DOI] [PubMed] [Google Scholar] 11.Huang Y., Mo H., Yang J., Gao L., Tao T., Shu Q., Guo W., Zhao Y., Lyu J., Wang Q., et al
Both represent transformative advances in metabolic health
